Lymphatic system

Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

Retrieved on: 
Wednesday, December 14, 2022
Protease, Cell, Maxim Ksenzov, CAR, Amyloidosis, Clinical trial, Multiple myeloma, MTD, Progression-free survival, Security (finance), Clinical Cancer Research, Neoplasm, TME, AL amyloidosis, Safety, Bone marrow, AL, LOS, Regulation, Neurotoxicity, Prognosis, ORR, International Myeloma Foundation, MD, CRS, Toxicity, Platform, Lymphatic system, B cell, MM, BCMA, Patient, ThinkEquity, Pharmaceutical industry, Medical imaging, Haematologica

NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients.

Key Points: 
  • NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients.
  • The formation of Nexcella, Inc is expected to have a minimal impact on Immix Biopharma’s financial position, as Nexcella, Inc is expected to be an independently financed company.
  • Learn more at www.immixbio.com
    This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events.
  • Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions.

Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

Retrieved on: 
Wednesday, December 14, 2022
Protease, Cell, Maxim Ksenzov, CAR, Amyloidosis, Clinical trial, Multiple myeloma, MTD, Progression-free survival, Security (finance), Clinical Cancer Research, Neoplasm, TME, AL amyloidosis, Safety, Bone marrow, AL, LOS, CFO, Regulation, Neurotoxicity, Prognosis, ORR, International Myeloma Foundation, MD, CRS, Toxicity, Platform, Lymphatic system, B cell, MM, BCMA, Patient, ThinkEquity, Pharmaceutical industry, Medical imaging, Haematologica

NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients.

Key Points: 
  • NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients.
  • These data were published in Haematologica https://doi.org/10.3324/haematol.2022.281628 (multiple myeloma) and Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637 (AL amyloidosis).
  • Immix Biopharma has formed a wholly-owned subsidiary, Nexcella, Inc., to develop and potentially commercialize NXC-201.
  • ThinkEquity LLC acted as advisor to Immix Biopharma in this transaction.

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

Retrieved on: 
Wednesday, December 14, 2022
Follicular lymphoma, Pain, Annual report, Lymphatic system, Diarrhea, Security (finance), Fatigue, HS, Infrared spectroscopy correlation table, MD, DL2, Blood, COVID-19, Mass spectrometry, Plasma, AD, FDA, Safety, Boston, Boston Business Journal, Risk, Șaeș, Leukemia, QT interval, Therapy, MDM2, Hodgkin lymphoma, Mayo Clinic, Immunomodulatory imide drug, Neoplasm, T-cell lymphoma, Human, Abscess, MYD88, Apoptosis, Biomarker, Day, Cycle, Patient, HV, Degenerative disease, PD, Science, Toxicity, Headache, Itch, STAT3, PGA, IND, Cancer, Medical device, Medical imaging, Vaccine, Pharmaceutical industry, Black Majesty, Dermatology, IRAK4, PBMC

The Phase 1a dose escalation portion of the trial is ongoing; dose level 1 (DL1, 0.05 mg/kg) has been completed with a total of four patients enrolled.

Key Points: 
  • The Phase 1a dose escalation portion of the trial is ongoing; dose level 1 (DL1, 0.05 mg/kg) has been completed with a total of four patients enrolled.
  • All patients were heavily pretreated with multiple prior lines of therapy and included three patients with solid tumors and one patient with cutaneous T-cell lymphoma.
  • Kymera is currently preparing to initiate a Phase 1 clinical trial evaluating the safety, tolerability, PK/PD and clinical activity of KT-253 in adult patients with liquid and solid tumors in 2023.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Retrieved on: 
Tuesday, December 13, 2022
Pit additive, Pancreatic cancer, Good, Lymphatic system, Security (finance), Neoplasm, Lincoln Park, Sale, Purchasing, Safety, Lymphoma, EDGAR, ARTEMIS, Cancer, News, Agreement, Toxic shock syndrome, LPC, Bill, AML, Form 10-K, Asset purchase agreement, Sumathi Best Television Current Reporting Award, TCR, Research, Therapy, Antigen, COVID-19, Patient, Pharmaceutical industry

Marker will retain full control as to the timing and amount of any sale of shares of common stock to LPC, subject to certain limitations specified in the Agreement, including those under Nasdaq listing rules.

Key Points: 
  • Marker will retain full control as to the timing and amount of any sale of shares of common stock to LPC, subject to certain limitations specified in the Agreement, including those under Nasdaq listing rules.
  • Marker maintains the right to terminate the Agreement at any time, at its discretion, without any additional cost or penalty.
  • "We believe that this Agreement with LPC enables flexible access to capital in an efficient manner," stated Peter L. Hoang, President and CEO of Marker.
  • Marker has agreed to file a registration statement with the SEC to register the resale by LPC of the shares of common stock to be purchased by LPC under the Agreement.

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Canadian Aviation Regulations, CD137, Cell, NK, CAR, Baylor College of Medicine, SAN, University, Security (finance), Memorial Sloan Kettering Cancer Center, Food, Assistant professor, Safety, Engineering, Cancer, Maintenance, Regulation of tobacco by the U.S. Food and Drug Administration, Multiple myeloma, Toxic shock syndrome, Exposition, ASH, CD38, CD54, Abstract, IPSC, MHC, Destiny, Lymphocyte, CD58, Gene therapy, Immune system, Research, Gene, Society, Ink, Patent, Therapy, Risk, University of Oslo, Lymphatic system, ADR, Daratumumab, BCMA, Cell engineering, Patient, Development, Vaccine

Conditioning chemotherapy, commonly used throughout the field of cell therapy, often results in hematologic toxicities, can limit the potential for administration of multiple doses, and can prohibit adoption as part of early-line treatment.

Key Points: 
  • Conditioning chemotherapy, commonly used throughout the field of cell therapy, often results in hematologic toxicities, can limit the potential for administration of multiple doses, and can prohibit adoption as part of early-line treatment.
  • CD38-targeted monoclonal antibody therapies, such as daratumumab, are approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma.
  • Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas

Retrieved on: 
Tuesday, December 13, 2022
Lymphatic system, Kidney, CXCR4, Clinical trial, Mantle cell lymphoma, Therapy, Lymphoma, BCR, Docetaxel, Copanlisib, PI3K, Università della Svizzera italiana, B-cell lymphoma, Rigidity, USI, MD, BTK, Fosun Pharma, Patient, Oncology, BLX, Research, Chronic lymphocytic leukemia, MTT, BCR-ABL, P13, Pharmaceutical industry, Fine chemical, Spexy Beast

Anti-proliferative activity was measured by the MTT assay in cell lines derived from mantle cell lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma.

Key Points: 
  • Anti-proliferative activity was measured by the MTT assay in cell lines derived from mantle cell lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma.
  • In addition, Spexis is analyzing existing BLX clinical and preclinical data to determine the appropriate development path forward, including potential new indications.
  • In line with this ongoing review, Spexis recently published data demonstrating synergistic efficacy in combination with docetaxel in metastatic prostate cancer.
  • Spexis is looking to partner either these pre-clinical leads or the entire platform itself, potentially in combination with complementary technologies.

Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma

Retrieved on: 
Monday, December 12, 2022
European Medicines Agency, EMA, University, CAR, PRIME, Oncology, Lymphatic system, Relapse, Hodgkin lymphoma, Food, FDA, Marketing, Poster, DNA, Lymphoma, Assistant professor, Priority, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TT11, Trial of the century, ASH, CD30, Hematological Cancer Research Investment and Education Act, CR, ORR, Neoplasm, CHL, Non-Hodgkin lymphoma, Stanford University, Associate professor, Research, Society, NHL, MD Anderson Cancer Center, Cancer, Therapy, Risk, Autotransplantation, Vaccine, Pharmaceutical industry, Patient

SINGAPORE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced updated clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy, were presented in a poster and oral podium presentation at the 64rd Annual Meeting of the American Society of Hematology (ASH). The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). Moreover, research identified circulating tumor DNA (ctDNA) analysis as a potential measure of response in cHL after CD30 targeted CAR T-cell therapy.

Key Points: 
  • The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL).
  • The ASH poster, titled, “Updated Results and Correlative Analysis: Autologous CD30.CAR-T Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial),” reported expanded data from the pilot segment of a Phase 2 trial of autologous CD30.CAR-T in patients with r/r cHL.
  • “The data presented at ASH 2022 continue to demonstrate the CD30.CAR-T cell therapy to be well tolerated with excellent anti-tumor responses in patients with relapsed or refractory classical Hodgkin lymphoma.
  • Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b).

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

Retrieved on: 
Monday, December 12, 2022
Follicular lymphoma, Annual report, Lymphatic system, Security (finance), Webcast, EHA, Phenotype, Tisagenlecleucel, CRS, ASH, Cure, B-ALL, Toxicity, Extranodal NK/T-cell lymphoma, nasal type, IQR, Lymphoma, COVID-19, CD22, Human, Acute leukemia, CAR, CNS, Lymphoid leukemia, Safety, CLL, Cancer, Bone marrow, University College London, B-cell lymphoma, T-cell lymphoma, Risk, MRD, Society, Peripheral T-cell lymphoma, ALL, UCL, Engineering, Doctor of Philosophy, ORR, Rate, NHL, TRBC1, Patient, Investigational New Drug, Cell, SCT, CD19, Toxic shock syndrome, Royal College of Pathologists, Blackstone, MCL, Therapy, Pharmaceutical industry, Vaccine, Medical device, MD, DLBCL

Importantly, we have not observed antigen negative relapse,” said Dr. Martin Pule, Chief Scientific Officer at Autolus.

Key Points: 
  • Importantly, we have not observed antigen negative relapse,” said Dr. Martin Pule, Chief Scientific Officer at Autolus.
  • “In the AUTO4 study, some patients have experienced durable metabolic CRs, including one patient up to the one-year mark.
  • A simultaneous audio webcast and replay will be accessible on the events section of Autolus website.
  • In collaboration with Autolus’ academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 12, 2022
IKZF3, Follicular lymphoma, BCL2, Chronic lymphocytic leukemia, Phase, Enzyme, IKZF1, ClinicalTrials.gov, Protein, Clinical trial, SAN, MTD, Mantle cell lymphoma, SKI, Lymphocytosis, KOL, Lymphoid leukemia, Safety, CLL, Cancer, Memorial Sloan Kettering Cancer Center, Pharmacokinetics, Exposition, MSCE, ASH, B-cell lymphoma, ORR, BTK, Non-Hodgkin lymphoma, Waldenström's macroglobulinemia, MCL, Society, Therapy, DLBCL, Lymphatic system, Index (publishing), COVID-19, Risk, Patient, SLL, Pharmaceutical industry

SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented additional positive clinical data from its Phase 1 clinical trial of NX-2127 in two oral sessions by Anthony Mato, M.D., MSCE, former director of the Chronic Lymphocytic (CLL) Program at Memorial Sloan Kettering Cancer Center, and Omar Abdel-Wahab, M.D., Chair of Sloan Kettering Institute (SKI) Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center. NX-2127 is a once daily, oral, investigational new drug that combines BTK degradation with immunomodulatory activity. The podium presentations took place at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition which is being held in New Orleans, Louisiana.

Key Points: 
  • The podium presentations took place at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition which is being held in New Orleans, Louisiana.
  • Approximately 78% of this group had previously received both BTK and BCL2 inhibitors and 35% had been treated with the non-covalent BTK inhibitor pirtobrutinib.
  • Of the CLL patients, 48% had one or more identified BTK resistance mutations prior to treatment with NX-2127.
  • These findings translated into clinically meaningful BTK degradation in the Phase clinical 1 trial and clinical activity independent of baseline BTK mutations.

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

Retrieved on: 
Monday, December 12, 2022
HSCT, Lymphatic system, Blood, Security (finance), Fatigue, Webcast, Principal investigator, Exposition, ASH, Infrared spectroscopy correlation table, Vomiting, CMV, AML, Hematopoietic stem cell transplantation, Cohort, COVID-19, Glioblastoma, Hematology-Oncology and Stem Cell Transplantation Research Center, Graft-versus-host disease, University, Clinical trial, Safety, CRS, Constipation, Society, KUCC, IPSC, Deltex Medical Group, Disease, Immune system, Medical director, Patient, Cytomegalovirus, Leukemia, Cytokine release syndrome, AES, Poster, Magnesium, CR, Acute myeloid leukemia, Risk, Event, Pharmaceutical industry, Medical imaging

As of December 9, 2022, four patients have received the first dose level (DL) of INB-100 (1 x 106 cells/kg) and remain on study and in remission.

Key Points: 
  • As of December 9, 2022, four patients have received the first dose level (DL) of INB-100 (1 x 106 cells/kg) and remain on study and in remission.
  • Steroid-responsive cutaneous acute Grade 1/2 graft-versus-host disease (GvHD) has been observed in all patients, with one patient experiencing Grade 2 intestinal GvHD.
  • Two patients have been enrolled and dosed in Cohort 2, evaluating INB-100 at a dose level of 3 x 106 cells/kg.
  • IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.